Key clinical point: The presence of antidrug antibodies was associated with a diminished response to biologic disease-modifying antirheumatic drugs (bDMARD) among patients with rheumatoid arthritis (RA), highlighting the importance of monitoring antidrug antibodies, particularly among nonresponders.
Major finding: At month 12, the prevalence of antidrug antibodies against rituximab (50.0%), anti-tumor necrosis factor monoclonal antibodies (38.2%), and tocilizumab (20.0%) was relatively high, and an inverse association was observed between antidrug antibody positivity for all bDMARD and the European Alliance of Associations for Rheumatology response (odds ratio 0.19; P < .001).
Study details: This cohort study used data from the ABI-RA prospective study to evaluate 230 patients with RA who initiated bDMARD.
Disclosures: The ABI-RA study was a part of ABIRISK, which was funded by the European Union and included financial contribution from the European Union’s Seventh Framework Programme and others. Several authors declared receiving personal fees, grants, or non-financial support from various sources.
Source: Bitoun S et al for the ABIRISK Consortium. Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies. JAMA Netw Open. 2023;6(7):e2323098 (Jul 12). doi: 10.1001/jamanetworkopen.2023.23098